Karolinska Institutet receives a 9.4 million SEK donation from Nordstjernan

The partners in Pandemic Antiviral Discovery (PAD) initiative has announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans. These grants mark the majority of the first investments to come from the PAD initiative, a global philanthropic collaboration […]

AstraZeneca’s COVID-19 vaccine, Vaxzevria, has been granted full Marketing Authorisation (MA) in the European Union (EU). Vaxzevria was originally granted a conditional Marketing Authorisation (cMA) due to the urgency of the COVID-19 pandemic. As there continues to be sufficient evidence of safety and efficacy confirming the benefits of Vaxzevria, the European Medicines Agency (EMA) has now granted a full […]

Evusheld, a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. “COVID-19 remains an ongoing health concern for millions of Europeans and around the world, especially for […]

Researchers at Karolinska Institutet are developing a coronavirus vaccine designed to be less sensitive to mutations and equipped for future strains. The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers now hope to be able to take it to safety studies on humans. “This is […]

Two ongoing research studies funded by NordForsk are providing new knowledge about COVID-19 related to pregnancy and mental health. The Nordic countries have similar welfare systems, access to high-quality health data, and publicly funded health services. Together with citizens’ trust in research, this all represents a particular strength in this context, describes NordForsk. Five collaborative […]

Bavarian Nordic has provided an update on the Phase 3 development of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The upcoming Phase 3 trial has been redesigned to include a licensed mRNA-based vaccine (Comirnaty) in the comparator arm of the study, to potentially support the primary objective of the study and demonstrate that the […]

New research from Karolinska Institutet shows that a booster shot of mRNA vaccine to individuals who have received two doses of inactivated vaccine offers the same level of protection against COVID-19 as three doses of mRNA vaccine. “Our results indicate that one booster shot of an mRNA vaccine, as a complement to the cheaper but […]